A local non-opioid solution to relieve pain after musculoskeletal surgery

A local non-opioid solution to relieve pain after musculoskeletal surgery

Slide

Slide

Why it matters

Surgeries from Orthopedics and Traumatology rank amongst the most painful interventions overall. Millions of musculoskeletal surgeries are performed annually and this number is increasing. Achieving adequate pain relief after musculoskeletal surgery is a major challenge. To date, opioids fulfil a central role in the treatment of postoperative pain, but there are increasing concerns about their use. Toxic side-effects of the systemic use of opioids can lead to insufficient relief of pain, malnutrition, delayed mobilization and unnecessary long hospital stay. Furthermore, opioids can be highly addictive even after relatively short periods of use.

The challenge

The medical community is searching for alternatives to opioids. In recent years the use of local anaesthetic techniques has increased with promising results. However, for many types of musculoskeletal surgeries no effective alternatives to opioids are available yet.

Periosteum

The most intense pain after musculoskeletal surgery is caused by local damage to the highly pain-sensitive periosteum, a thin nerve-rich layer surrounding each bone in the body.

 

Local

Similar to dental procedures which are often performed completely painless by virtue of local anaesthetics, periosteal pain may also be controlled locally.

 

Anaesthetic

The challenge with pain relief for musculoskeletal surgery is that anaesthetics must be delivered and stay precisely at the damaged periosteum in order to locally block pain.

 

The challenge

The medical community is searching for alternatives to opioids. In recent years the use of local anaesthetic techniques has increased with promising results. However, for many types of musculoskeletal surgeries no effective alternatives to opioids are available yet.

Periosteum

The most intense pain after musculoskeletal surgery is caused by local damage to the highly pain-sensitive periosteum, a thin nerve-rich layer surrounding each bone in the body.

 

Local

Similar to dental procedures which are often performed completely painless by virtue of local anaesthetics, periosteal pain may also be controlled locally.

 

Anaesthetic

The challenge with pain relief for musculoskeletal surgery is that anaesthetics must be delivered and stay precisely at the damaged periosteum in order to locally block pain.

 

The solution

SentryX is developing a hydrogel combined with an approved anaesthetic. This hydrogel is inserted at the surgical site and covers the damaged periosteum, without interrupting the routine surgical workflow. Once in place, the hydrogel gradually releases the anaesthetic on the periosteum, and completely degrades afterwards.

Our innovation is being developed to better combat postoperative pain, to speed up hospital discharge and recovery and help prevent dependence on opioids in the critical rehabilitation phase.

Status

Collaboration

  • University Medical Center Utrecht
  • Faculty Pharmacy of University Utrecht
  • Industrial partners

Technology

  • Multiple patents
  • Designed for surgical interventions
  • Exploration into broader applications

Development plan

  • 2021: final GLP preclinical study
  • 2021: International observational study
  • 2022: International clinical trial

Collaboration

  • University Medical Center Utrecht
  • Faculty Pharmacy of University Utrecht
  • Industrial partners

Technology

  • Multiple patents
  • Designed for surgical interventions
  • Exploration into broader applications

Development plan

  • 2021: final GLP preclinical study
  • 2021: International observational study
  • 2022: International clinical trial

Our company

Founders

Jorrit-Jan Verlaan
Jorrit-Jan Verlaan
Co-founder and Chief Scientific Officer
Jorrit-Jan (JJ) Verlaan is a spine surgeon from the University Medical Center Utrecht with a special interest in improving clinical outcome by tailoring treatment through a multidisciplinary approach. With his team, he developed innovative surgical and non-surgical procedures that have been published and adopted worldwide for the benefit of, especially, cancer patients. Professor Verlaan is past chairman of the Research and Innovation Committee of the Dutch Orthopedic Association and currently serves as director of the Orthopedic residency program and is also a member of the AO Spine Tumor Knowledge Forum.
Bas Oosterman
Bas Oosterman
Co-founder and CEO
Bas Oosterman has gained a multi-disciplinary background at various innovative companies. Before starting SentryX he served as Chief Operating Officer of a Clinical Research Organisation and worked for Philips Electronics in various positions. He studied Econometrics, received his PhD degree in Management and Organization, and is a (six sigma) Black Belt. His PhD thesis dealt with speeding up the time-to-market of new product innovation projects.

Scientific advisors

Marianna Tryfonidou
Marianna Tryfonidou
Scientific advisor
Marianna Tryfonidou is professor in regenerative orthopedics at the Utrecht University. She is a certified veterinary surgeon for companion animals and has expertise in translational research. She coordinates the iPSpine consortium that was recently awarded €15 million under the Horizon 2020 program developing an advanced therapy for chronic low back pain.
Raymond Schiffelers
Raymond Schiffelers
Scientific advisor
Raymond Schiffelers is professor of Nanomedicine at the UMC Utrecht. He is specialized in drug delivery and drug targeting. Currently he coordinates two EU H2020 projects B-Smart & Expert and participates in several EU and national projects on nanomedicine.
Jos Malda
Jos Malda
Scientific advisor
Professor Jos Malda is Head of Research at the Department of Orthopedics, University Medical Center Utrecht and at the Department of Equine Sciences, University of Utrecht. He also leads the Utrecht Biofabrication Facility.

Advisors

Koen de Heus
Koen de Heus
Advisor
Koen de Heus is CEO and shareholding family member of the Royal De Heus Group, an international company with a global top-15 position in the animal nutrition industry. Currently, De Heus has operating activities in 18 countries with a total revenue of 3 billion Euro and 6000 employees. Additionally, De Heus has considerable interests in companies in the value chain to support animal nutrition activities and promote animal health.
Jeroen de Haas
Jeroen de Haas
Advisor
Jeroen de Haas is former CEO of sustainable energy company ENECO. De Haas holds several supervisory and advisory roles including chairman of the supervisory board of Royal Wagenborg, member of the supervisory board of Port of Amsterdam, chairman of the board of NPM Energy, and member in the supervisory board of RegMed XB. He is partner in private equity company Prorsum Capital in Zurich. Prorsum invests in three areas of the sustainable development goals: water, mobility, and energy. De Haas focuses in all his activities on the triangle sustainability-innovation-digitization.

Due to his responsibilities/duties at the American Academy of Orthopedic Surgeons and North American Spine Society Dr. Vaccaro has temporarily suspended his advisory activities at SentryX.